首页>投融资
Calida Therapeutics
种子轮
Calida Therapeutics是一家总部位于法国巴黎的临床前阶段生物技术公司,任务是开发单克隆抗体来治疗和预防血栓炎性疾病。Calida 旨在成为血栓炎症性疾病新领域的领导者旨在成为血栓炎症性疾病新领域的领导者。这些发生在广泛的适应症中,从心血管疾病到自身免疫性疾病的并发症。其新颖的方法旨在通过防止血小板和骨髓细胞之间的串扰来破坏血栓形成和炎症之间的分子联系,从而消除这两种可能导致组织损伤和危及生命的现象的连锁反应。
基本信息
-
公司全称Calida Therapeutics
-
类型防血栓炎性疾病治疗研究商
-
产业领域药品研发/制造、生物药
-
公司人数15人以下
-
地址
-
联系电话
-
邮箱
-
成立时间2022-01-01
投融资
-
2023-04-06种子轮200万欧元AdBio partners
-
2023-04-06种子轮200万欧元AdBio partners
相关投融资企业
捐赠/众筹/授予
igaTx 是一家生物技术公司,开发工程化单体 IgA 中性粒细胞接合器,以释放中性粒细胞对癌症的肿瘤杀伤能力,以及针对传染病的工程化二聚体 IgA 杀伤能力。该公司在工程治疗性 IgA 方面的前沿方法基于 Jeanette Leusen 教授在乌得勒支医学中心(荷兰乌得勒支)进行的开创性工作,并广泛适用于许多不同疾病。
C轮
SiteOne Therapeutics, founded by Stanford University, is a biotechnology company focused on the development of long-acting analgesics, non-norcotic analgecis and diagnostic imaging agents for pain and cancer.In May 2023, SiteOne Therapeutics Inc received a grant for up to $15 million from the National Institute on Drug Abuse.In January 2017, the company raised $15 million in a series B round of financing
A轮
PsiOxus Therapeutics Ltd was formed from the merger of Myotec Therapeutics and Hybrid BioSystems in December 2010. The company is focused on the development of novel therapeutics that address cancer and other clinically unmet diseases.Myotec Therapeutics was a spin-out from Imperial Innovations and was set up to develop technology originated at Imperial College London. It focused on repurposing drugs for the treatment of cachexia, with the intention of out-licensing after completion of phase II studies.In June 2017, the company expanded its operations into a 21,000 sq ft state-of-the-art facility on the Abingdon Science Park in Oxfordshire, UK and a new US facility in Plymouth Meeting near Philadelphia, PA.In April 2012, PsiOxus announced that it would expand into new facilities at the Milton Park in Oxfordshire, UK. The expansion would include a bespoke laboratory for the research and development of novel viral therapeutics; later that month, the facility was opened.By Decem